

4 (Twice-Amended). A method in accordance with claim 16, wherein said method is for ameliorating the effects of a disease selected from the group consisting of diabetic neuropathy, senile dementia, Alzheimer's disease, Parkinson's Disease, facial nerve (Bell's) palsy, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, non-arteritic optic neuropathy, and vitamin deficiency, and wherein said human is one having said disease.

5 (Twice-Amended). A method in accordance with claim 16, wherein said method is for ameliorating the effects of a disease which is not an autoimmune disease or a neoplasm, and wherein said human is one having said disease.

16 (Amended). A method of (ameliorating the degenerative effects) of injury or disease on the central nervous system or peripheral nervous system, by preventing or inhibiting axonal degeneration and/or promoting nerve regeneration, (comprising administering to a human in need thereof an effective amount for neuroprotection of a composition comprising an agent selected from the group consisting of:

- (a) non-recombinant, NS-specific antiseif activated T-cells;
- (b) a NS-specific antigen or a derivative thereof;

cn't  
D<sub>2</sub>  
C<sub>2</sub>  
(c) a peptide derived from a NS-specific antigen or  
a derivative thereof;

(d) a nucleotide sequence encoding a NS-specific  
antigen;

(e) a nucleotide sequence encoding a peptide  
derived from a NS-specific antigen; and

(f) any combination of (a)-(e).

---